TLK1B Inhibitor, Antiandrogen Prostate Cancer Treatment Patent
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Targeting the TLK1/NEK1 axis in prostate cancer
Grant US12611412B2 Kind: B2 Apr 28, 2026
Assignee
Board of Supervisors of Louisana State University and Agricultural and Mechanical College
Inventors
Arrigo DeBenedetti, Siddhant Bhoir, Vibha Singh, Javeena Hussain, Rupesh Chikhale, Richard Bryce, Sivapriya Kirubakaran
Abstract
A method of treating prostate cancer in a patient comprising administering to the patient a pharmaceutical composition including a first therapeutic including a TLK1B inhibitor, or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, and a second therapeutic including an antiandrogen or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof.
CPC Classifications
A61K 31/5415 A61K 31/167 A61P 35/00
Filing Date
2023-11-15
Application No.
18509586
Claims
20
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.